These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 38244662)

  • 1. Nanoparticle-integrated dissolving microneedles for the co-delivery of R848/aPD-1 to synergistically reverse the immunosuppressive microenvironment of triple-negative breast cancer.
    Huang S; Wen T; Wang J; Wei H; Xiao Z; Li B; Shuai X
    Acta Biomater; 2024 Mar; 176():344-355. PubMed ID: 38244662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
    Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
    Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting tumor-associated macrophages with mannosylated nanotherapeutics delivering TLR7/8 agonist enhances cancer immunotherapy.
    Dang BN; Duwa R; Lee S; Kwon TK; Chang JH; Jeong JH; Yook S
    J Control Release; 2024 Aug; 372():587-608. PubMed ID: 38942083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune.
    Jiang Z; Cai G; Liu H; Liu L; Huang R; Nie X; Gui R; Li J; Ma J; Cao K; Luo Y
    J Nanobiotechnology; 2024 May; 22(1):296. PubMed ID: 38811964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy.
    Yang P; Lu C; Qin W; Chen M; Quan G; Liu H; Wang L; Bai X; Pan X; Wu C
    Acta Biomater; 2020 Mar; 104():147-157. PubMed ID: 31904558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
    J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
    Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
    Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient TNBC immunotherapy by dual reprogramming tumor-infiltrating dendritic cells and tumor-associated macrophages with stimulus-responsive miR155 nanocomplexes.
    Jing Z; Li Y; Song J; Zang X
    Int J Biol Macromol; 2023 Dec; 253(Pt 3):126912. PubMed ID: 37722648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
    Chen C; Guo Q; Fu H; Yu J; Wang L; Sun Y; Zhang J; Duan Y
    Biomaterials; 2021 Aug; 275():120988. PubMed ID: 34186238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microneedles loaded with anti-PD-1-cisplatin nanoparticles for synergistic cancer immuno-chemotherapy.
    Lan X; Zhu W; Huang X; Yu Y; Xiao H; Jin L; Pu JJ; Xie X; She J; Lui VWY; Chen HJ; Su YX
    Nanoscale; 2020 Sep; 12(36):18885-18898. PubMed ID: 32902555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity.
    Mei S; Peng S; Vong EG; Zhan J
    Int Immunopharmacol; 2024 Feb; 128():111579. PubMed ID: 38278066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
    Gao M; Wang T; Ji L; Bai S; Tian L; Song H
    Front Immunol; 2020; 11():366. PubMed ID: 32194569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
    Chen XY; Li B; Wang Y; Jin J; Yang Y; Huang LH; Yang MD; Zhang J; Wang BY; Shao ZM; Ni T; Huang SL; Hu XC; Tao ZH
    Cancer Commun (Lond); 2023 Sep; 43(9):1003-1026. PubMed ID: 37434394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment.
    Wu J; Wang W; Gao L; Shao X; Wang X
    Cancer; 2024 Apr; 130(S8):1449-1463. PubMed ID: 38482921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
    Yang Z; Sun JK; Lee MM; Chan MK
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Intelligent Biomimetic Nanoplatform for Holistic Treatment of Metastatic Triple-Negative Breast Cancer
    Cheng Y; Chen Q; Guo Z; Li M; Yang X; Wan G; Chen H; Zhang Q; Wang Y
    ACS Nano; 2020 Nov; 14(11):15161-15181. PubMed ID: 33143424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.